EZZ Life Science Holdings (ASX:EZZ), a genomic life sciences company specialising in scientifically formulated supplements and skincare, is accelerating its global growth strategy. In tihs presentation, Non-Executive Chair Glenn Cross highlights a strong financial performance in FY25 to date, including $45.8m in receipts, $21.1m in cash, and operating cash flow up 73% on the prior period. Gross margins remain robust at 77%.
The company markets 63 SKUs across seven countries, with top-performing products including lysine-based bone growth supplements and high-strength DHA. Cross emphasises the company’s data-driven product development, leveraging insights from Shopify, Tmall, Douyin and Amazon to guide formulation and design. All products are manufactured under GMP conditions, with regulatory compliance across markets including TGA and FDA.
EZZ is now entering the US market with a newly developed brand, “EZZ Day”, and four FDA-registered products. It has commenced sales via a Shopify store and plans an Amazon launch with influencer-led marketing. Products for the US will be locally manufactured in GMP-certified facilities to meet consumer preferences and avoid tariff risks.
In Southeast Asia, EZZ has signed a three-year, $21m minimum commitment distribution agreement with ROFA Enterprises. The deal covers Thailand, Vietnam, and Singapore through 10,000 retail points and marks a major step in regional expansion. The company has also flagged further exploration in Japan, Turkey, and Malaysia.
Watch Chair Glenn Cross deliver the full investor presentation and outline EZZ’s strategy for global expansion, product innovation, and rising margins.
